Diligence memo · auto-generated · as of July 2, 2026

LunaPBC, Inc.

LunaPBC, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

LunaPBC, Inc. operates in Biotechnology, based in SAN DIEGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

LunaPBC, Inc. has raised $11M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $4.6M on 2018-11-09.

Most recent recorded round closed around 2021-05-11.

Valuation (modeled)modeled

Provath models LunaPBC, Inc. at approximately $91M (range $4.1M–$405M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.50× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 21 months.

Last raise 5.1 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 59% of Biotechnology peers (4293 compared).

Modeled value ranks above 57% of those peers.

Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.